In a diverse population of 211 adults with type 2 diabetes, a mean reduction in (HbA1c) of 1.2%-points was observed after 30 weeks of treatment with once-weekly semaglutide.
Of the participants who completed the study, 70.5% achieved an HbA1c target of less than 8.0%.
Participants experienced a mean weight loss of 7.8 kg, reflecting a relative reduction of 7.5%.
decreased by an average of 8.8 cm.
Improvements in health-related quality of life and treatment satisfaction were noted across most domains of the Short-Form 36 Health Survey.
One serious adverse drug reaction was reported, along with eight cases of severe or documented hypoglycemia.
Simplified
INTRODUCTION: SURE Netherlands (NCT03929679) evaluated the use of once-weekly (OW) semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1RA), in routine clinical care for individuals with type 2 diabetes (T2D).
METHODS: Adults (age ≥ 18 years) with T2D were enrolled into the single-arm study. The primary endpoint was change from baseline to end of study (EOS; approx. 30 weeks) in glycated haemoglobin (HbA). Secondary endpoints were change from baseline to EOS in (BW) and (WC). Proportions of participants achieving predefined HbAtargets and weight-loss responses at EOS, safety, health-related quality of life (HRQoL) and treatment satisfaction were assessed. 1c1c
RESULTS: In total, 211 participants (mean age 60.5 years; diabetes duration 13.3 years) initiated semaglutide; most were receiving metformin (82.9%) and/or basal insulin (59.2%) at baseline, and 6.2% switched from another GLP-1RA. Mean baseline HbA, BW and WC were 8.6%, 105.2 kg and 118.8 cm. In the 186 (88.2%) participants receiving semaglutide at EOS, mean reduction in HbAwith semaglutide was - 1.2%-points (95% [confidence interval] CI - 1.3; - 1.0; p < 0.0001), with 124 (70.5%), 95 (54.0%) and 65 (36.9%) participants achieving HbAtargets of < 8.0%, < 7.5% and < 7.0%, respectively. Mean reduction in BW was - 7.8 kg [95% CI - 8.7; - 6.8; p < 0.0001], corresponding to relative reduction of - 7.5% [95% CI - 8.4; - 6.6; p < 0.0001]. Improvements in WC (- 8.8 cm [95% CI - 10.4; - 7.2; p < 0.0001]), HRQoL and treatment satisfaction were observed, including across most Short-Form 36 Health Survey domains. One serious adverse drug reaction (cholecystitis) was reported. Eight participants (all receiving concomitant insulin) experienced severe or documented hypoglycaemia. 1c1c1c
CONCLUSION: Individuals with T2D treated with OW semaglutide experienced significant and clinically relevant improvements in glycaemic control and BW from baseline. These results from a diverse real-world population in the Netherlands support the use of OW semaglutide in treating adults with T2D in routine clinical practice.
Key numbers
-1.2%-points
HbA Reduction
Mean change from baseline to end of study
-7.8 kg
Weight Loss
Mean change from baseline to end of study
124 of 176
Participants Achieving HbA Targets
Achieved HbA < 8.0% at end of study
Full Text
We can’t show the full text here under this license.
